Malignant Melanoma
Moderna's personalised mRNA vaccine and melanoma recurrence: what the phase 2b trial actually showed, and what comes next
The personalised mRNA-4157 (V940) vaccine combined with pembrolizumab after complete resection of melanoma prolonged recurrence-free survival compared with pembrolizumab alone in the randomised phase 2b KEYNOTE-942 trial (Lancet 2024, n=157: 107 vs 50 patients). At 18 months, 79% of patients in the …
Read the full story →First successful phase 3 trial of a personalised mRNA cancer vaccine in melanoma (INTerpath-001)
The phase 3 INTerpath-001 trial met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in 1,137 patients with completely resected stage IIB-IV cutaneous melanoma, randomised 2:1 to the personalised mRNA vaccine intismeran …
Read the full story →Oncolytic virotherapy RP1 plus nivolumab approved for anti-PD-1-refractory melanoma (ORR 32.9% in IGNYTE)
The FDA granted accelerated approval to vusolimogene oderparepvec (RP1, Tudriqev) combined with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on an anti-PD-1 antibody-based regimen — a group with very limited options. In the IGNYTE trial (Journal of Clinical Onco…
Read the full story →